Nurse-led preemptive symptom management for head and neck cancer patients during radiation therapy
Official title: Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Undergoing Radiation Therapy
Run by West China Hospital · NCT07467083 · Data updated 2026-11-12
This project will try a nurse-led preemptive symptom management protocol to see if it reduces radiation therapy interruptions and eases symptoms for adults receiving radiotherapy for head and neck cancer.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 170 (estimated) |
| Sponsor | West China Hospital Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Chengdu, Sichuan) |
| Status | Recruiting |
| Started | March 15, 2026 |
| Main results expected | March 1, 2027 |
| Study ends | March 1, 2027 |
| Registry record updated | April 1, 2026 |
| Trial ID | NCT07467083 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18) with pathologically confirmed malignant head and neck tumors without distant metastasis, scheduled for postoperative adjuvant or radical radiotherapy (with or without chemotherapy), with baseline ECOG 0–2 and the ability to complete questionnaires.
✕Probably not a fit
Patients with prior head and neck radiotherapy, other active malignancies, significant uncontrolled systemic disease, or cognitive/mental impairments are unlikely to benefit or be eligible for this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with confirmed non-metastatic head and neck cancer who are scheduled for postoperative adjuvant or radical radiotherapy (with or without concurrent chemotherapy) will be enrolled at West China Hospital. Participants will receive either a nurse-led preemptive symptom management protocol delivered throughout the radiotherapy course or conventional care, with procedures and contacts occurring in person at the treatment center. The primary outcome is the rate of radiation therapy interruptions; secondary outcomes include symptom severity, quality of life, and psychological well-being measured by validated questionnaires. Data will be compared between the two groups to determine whether the preemptive nursing protocol reduces interruptions and improves patient-reported outcomes.
Why it matters
Potential benefit: If successful, the nurse-led preemptive protocol could lower radiation treatment interruptions and improve symptoms, quality of life, and psychological well-being during radiotherapy.
How similar studies have gone: Nurse-led and proactive symptom-management programs in oncology have shown benefits in reducing symptoms and care disruption, but preemptive protocols specifically tailored to head and neck radiotherapy are less common and still being tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients had pathologically confirmed malignant head and neck tumors without distant metastasis. 2. Patient age ≥18 years; Patients were scheduled to undergo either postoperative adjuvant radiotherapy or radical radiotherapy, with or without concurrent chemotherapy. 3. Baseline ECOG (Eastern Cooperative Oncology Group) score 0-2; 4. Good cognitive and reading skills, able to complete the questionnaire survey. Exclusion Criteria: 1. Presence of other malignant tumors aside from head and neck malignancies; 2. A history of prior head and neck radiotherapy; 3. Mental illness or cognitive impairments; 4. Uncontrolled systemic diseases that could significantly affect their QoL.
Where it's running
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Phenotype-based Pain Guidance for Head and Neck Cancer-Related Pain (pilot)
This pilot test sees if tailoring pain treatment to a patient’s pain type can reduce head and neck cancer pain in adults who haven’t started cancer treatment yet.
-
Airway ultrasound in head and neck cancer patients
This observational study tests whether neck ultrasound measurements of the airway match CT measurements in adults with maxillofacial cancer undergoing surgery with anesthesia.
-
Safe use of metformin and naproxen to help prevent cancer in people with Fanconi anemia
This study tests whether metformin and naproxen can lower the chance of cancer developing in adults with Fanconi anemia.
-
Iparomlimab and Tuvonralimab With Cetuximab Before Surgery in Resectable Oral Cancer
In this phase 2 study, patients with locally advanced, resectable oral squamous cell carcinoma will receive a combination of iparomlimab, tuvonralimab, and cetuximab before surgery to see if the treatment is safe and can shrink tumors.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
-
Using Silverlon for head and neck patients with tracheostomies
This early-phase study tests whether Silverlon dressings can prevent severe skin reactions under tracheostomy collars in adults with head and neck cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.